Vikram M Narayan
Overview
Explore the profile of Vikram M Narayan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bilen M, Vo B, Liu Y, Greenwald R, Davarpanah A, McGuire D, et al.
Nat Cancer
. 2025 Feb;
PMID: 40016487
Cabozantinib is an oral multikinase inhibitor approved for treatment in metastatic renal cell carcinoma (RCC). We conducted a phase 2, nonrandomized, single-arm clinical trial (NCT04022343) of cabozantinib treatment for 12...
2.
Cardenas M, Prokhnevska N, Sobierajska E, Gregorova P, Medina C, Valanparambil R, et al.
Nature
. 2024 Nov;
635(8039):E9.
PMID: 39506126
No abstract available.
3.
Cardenas M, Prokhnevska N, Sobierajska E, Gregorova P, Medina C, Valanparambil R, et al.
Nature
. 2024 Oct;
636(8041):224-232.
PMID: 39443797
The T cell response to cancer controls disease progression and response to immunotherapy. Despite extensive knowledge regarding CD8 T cells, how CD4 T cells contribute to this process is less...
4.
Narayan V, Tholomier C, Mokkapati S, Martini A, Caruso V, Goudarzi M, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39406613
Background And Objective: Urinary tumor DNA (utDNA) profiling identifies mutations associated with urothelial carcinoma and can be used to detect minimal residual disease (MRD). We evaluate the utility of utDNA...
5.
Lotan Y, Krishna V, Abuzeid W, Launer B, Chang S, Krishna V, et al.
J Urol
. 2024 Oct;
213(2):192-204.
PMID: 39383345
Purpose: There are few markers to identify those likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG). We developed and validated artificial intelligence (AI)-based histologic assays that...
6.
Kilbridge K, Patil D, Filson C, Shelton J, Thomson S, Rosenbaum C, et al.
Cancer
. 2024 Sep;
130 Suppl 20:3602-3611.
PMID: 39254372
Background: Poor comprehension of prostate cancer (PCa) medical terms can create barriers to PCa treatment discussions. The authors measured comprehension of PCa terms and its relationship to health literacy in...
7.
Bilen M, Vo B, Liu Y, Greenwald R, Davarpanah A, McGuire D, et al.
Res Sq
. 2024 Aug;
PMID: 39149474
Cabozantinib is an oral multikinase inhibitor approved for treatment in metastatic renal cell carcinoma (RCC). We hypothesized that neoadjuvant cabozantinib could downstage localized tumors, facilitating partial nephrectomy, and facilitating surgery...
8.
Lim A, Westerman M, Korokovic A, Matulay J, Narayan V, Navai N
Bladder Cancer
. 2024 Jul;
8(2):193-209.
PMID: 38993364
Background: The benefit of surgery of the primary tumor in metastatic bladder cancer is unknown. Objective: Perform a comprehensive contemporary literature review on the benefit of surgery of the primary...
9.
10.
Martini D, Case K, Gratz D, Pellegrini K, Beagle E, Schneider T, et al.
Cancer
. 2024 Jul;
130(21):3658-3670.
PMID: 38959291
Background: Bladder cancer with divergent differentiation (BCDD) comprises a heterogenous group of tumors with a poor prognosis, and differential expression of nectin-4 and programmed death ligand-1 (PD-L1) has been reported...